Abstract:Aim: To review the main pathological findings of Neuromyelitis Optica Spectrum Disorder (NMOSD) associated with the presence of autoantibodies to aquaporin-4 (AQP4) as well as the mechanisms of astrocyte dysfunction and demyelination. Methods: An comprehensive search of the literature in the field was carried out using the database of The National Center for Biotechnology Information from . Systematic searches were performed until July 2022. Results: NMOSD is an inflammatory and demyelinating disease of the central nervous system mainly in the areas of the optic nerves and spinal cord, thus explaining mostly the clinical findings. Other areas affected in NMOSD are the brainstem, hypothalamus, and periventricular regions. Relapses in NMOSD are generally severe and patients only partially recover. NMOSD includes clinical conditions where autoantibodies to aquaporin-4 (AQP4-IgG) of astrocytes are detected as well as similar clinical conditions where such antibodies are not detected. AQP4 are channel-forming integral membrane proteins of which AQ4 isoforms are able to aggregate in supramolecular assemblies termed orthogonal arrays of particles (OAP) and are essential in the regulation of water homeostasis and the adequate modulation of neuronal activity and circuitry. AQP4 assembly in orthogonal arrays of particles is essential for AQP4-IgG pathogenicity since AQP4 autoantibodies bind to OAPs with higher affinity than for AQP4 tetramers. NMOSD has a complex background with prominent roles for genes encoding cytokines and cytokine receptors. AQP4 autoantibodies activate the complement-mediated inflammatory demyelination and the ensuing damage to AQP4 water channels, leading to water influx, necrosis and axonal loss. Conclusions: NMOSD as an astrocytopathy is a nosological entity different from multiple sclerosis with its own serological marker: immunoglobulin G-type autoantibodies against the AQP4 protein which elicits a complement-dependent cytotoxicity and neuroinflammation. Some patients with typical manifestations of NMSOD are AQP4 seronegative and myelin oligodendrocyte glycoprotein positive. Thus, the detection of autoantibodies against AQP4 or other autoantibodies is crucial for the correct treatment of the disease and immunosuppressant therapy is the first choice.

Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders

Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD

A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder

Disease-modifying treatments for neuromyelitis optica spectrum disorder in the context of a new generation of biotherapies

Treatment of neuromyelitis optica: state-of-the-art and emerging therapies

Advances in disease-modifying therapy of neuromyelitis optica spectrum disorders

Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: from Bench to Bedside

Application progress of disease modifying drugs in neuromyelitis optica spectrum disorder

Comparisons of Clinical Phenotype, Radiological and Laboratory Features, and Therapy of Neuromyelitis Optica Spectrum Disorder by Regions: Update and Challenges.

Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options

Risk of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder: Recognition and Preventive Strategy

Contemporary management challenges in seropositive NMOSD

Brain and spinal cord atrophy in NMOSD and MOGAD: Current evidence and future perspectives

Neuromyelitis Optica Spectrum Disorder in Latin America: State-of-the-Art and Current Challenges

Advances in Disease-Modifying Therapy of Neuromyelitis Optic Spectrum Disorders

Research progress on pathogenesis and clinical treatment of neuromyelitis optica spectrum disorders (NMOSDs)

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease

Adverse Events in NMOSD Therapy

Neuromyelitis optica spectrum disorder: pathophysiological approach

NMOSD Acute Attack: Understanding, Treatment and Innovative Treatment Prospect